TrialThe Pediatric infectious disease journal2014

Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.

Mark Cotton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.